Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIDSVAX B
- Development stage
- Discontinued
- Lead developer
- Diadexus
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**AIDSVAX B** is an investigational monovalent recombinant protein-subunit HIV-1 vaccine originally developed at Genentech and subsequently advanced by VaxGen. It contains recombinant HIV-1 subtype B envelope glycoprotein gp120 derived from the MN strain and was designed to induce gp120-binding and virus-neutralizing antibody responses that could prevent HIV-1 attachment and entry into susceptible host cells. AIDSVAX B was an early predecessor of the bivalent AIDSVAX B/B and AIDSVAX B/E vaccine products; it is not the same product as either bivalent formulation. Development of the AIDSVAX program did not result in an approved HIV vaccine.
- Brand names
- AIDSVAX B
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on AIDSVAX B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIDSVAX B.